Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz
The Effect of Efavirenz and Ritonavir-boosted Darunavir on the Pharmacokinetics of the HMG CoA Reductase Inhibitor Pitavastatin
Sponsor: Kowa Pharmaceuticals America, Inc.
This PHASE1 trial investigates HIV and Hyperlipidemia and is currently completed. Kowa Pharmaceuticals America, Inc. leads this study, which shows 9 recorded versions since 2012 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
▶ Show 4 earlier versions
-
Jun 2019 — Sep 2020 [monthly]
Unknown Status PHASE1
-
Jun 2018 — Jun 2019 [monthly]
Unknown Status PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1
First recorded
May 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kowa Pharmaceuticals America, Inc.
- NYU Langone Health
- New York City Health and Hospitals Corporation
- University at Buffalo
For direct contact, visit the study record on ClinicalTrials.gov .